ClinicalTrials.gg
Sign In
Not yet recruitingNCT07634822Updated Jun 9, 2026

Heart Failure and Postoperative Outcome in Surgery - a National Registry Study

An observational study in Heart Failure, Diastolic Heart Failure and Systolic Heart Failure, sponsored by Umeå University. Not yet recruiting at 2 sites in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-09.

Sponsored by Umeå University · Observational

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
2,200,000
Ages
18 Years and older
Sex
All
01

Study summary

The study is an exploratory study that aims to explore the incidence of heart failure in a national surgical cohort, and to compare postoperative mortality and morbidity in patients with and without heart failure. Furthermore, we want to investigate differences in the incidence of heart failure and its impact on postoperative morbidity and mortality in day surgery compared to inpatient surgery.

02

Conditions studied

  • Heart Failure
  • Diastolic Heart Failure
  • Systolic Heart Failure
03

In context

Heart Failure

6,331 studies on the registry are indexed under Heart Failure; 1,396 are open to participants now.

This study's planned enrollment of 2,200,000 is above the median of 200 across 1,983 observational studies indexed under Heart Failure.

Browse Heart Failure studies →

Lead sponsor

Umeå University is the lead sponsor of 272 studies on the registry; 60 are open to participants now.

Browse Umeå University studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients ≥18 years of age who underwent surgery in Sweden between 1 Jan 2021-31 Dec 2024.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥18 years of age who underwent surgery in Sweden between 1 Jan 2021-31 Dec 2024 and SPOR registered operation.

Exclusion criteria

Exclusion Criteria:

  • ASA 6 (deceased patient, organ donation).
  • Cardiac surgery
05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
2,200,000 participants (estimated)
Target follow-up
1 Year
Patient registry
Yes

Groups and cohorts

  • Surgery with SPOR registration

    Surgery registered in SPOR registry between 2021--2024

06

What researchers measure

Primary outcomes

  1. Postoperative mortality

    How does a heart failure diagnosis affect postoperative mortality at 30 days, 90 days, 180 days, and 365 days?

    Time frame: 365 days

  2. Postoperative morbidity

    How does a heart failure diagnosis associated with postoperative morbidity at 30 days?

    Time frame: 30 days postoperative

Secondary outcomes

  1. Prevalence of heart failure

    What is prevalence of heart failure in surgery in Sweden?

    Time frame: 5 years preoperative

Other outcomes

  1. Differences between ambulatory and inpatient surgery

    Is there difference between ambulatory respective elective surgery regarding mortality and morbidity after surgery?

    Time frame: 365 postoperative

  2. Difference in prevalence of heart failure

    Is there difference in prevalence regarding ambulatory and inpatient surgery

    Time frame: 5 years preoperative

07

Study locations

2 sites
  • Region Norrbotten, department of Anesthesia and Intensive Care, Sunderby Hospital
    Luleå, Sweden
    • Tomi Myrberg, Associate professor · Principal investigator
  • Institution for Diagnostic and Intervention, dep of Anestesiology and Intensive care
    Umeå, Sweden
    • Tomi Myrberg, Associate professor · Contacttomi.myrberg@umu.se · +46920282236
    • Tomi Myrberg, Associate professor · Principal investigator
08

References and documents

Publications

  • 1. Griffiths R, Beech F, Brown A, Dhesi J, Foo I, Goodall J, et al. Peri-operative care of the elderly 2014: Association of Anaesthetists of Great Britain and Ireland. Anaesthesia. 2014;69 Suppl 1:81-98. 2. Weiser TG, Haynes AB, Molina G, Lipsitz SR, Esquivel MM, Uribe-Leitz T, et al. Estimate of the global volume of surgery in 2012: an assessment supporting improved health outcomes. Lancet. 2015;385 Suppl 2:S11. 3. Eriksson J, Sandberg C, Kilhamn N, Bell M, Oldner A, Larsson E. Surgery in patients aged ≥ 80 years: mortality and recovery in a nationwide cohort study. Anaesthesia. 2025;80(7):812-22. 4. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. European journal of heart failure. 2022;24(1):4-131. 5. Lindberg F, Benson L, Dahlström U, Lund LH, Savarese G. Trends in Heart Failure Mortality in Sweden Between 1997 and 2022. European journal of heart failure. 2024;27(2):366-76. 6. Shah KS, Xu H, Matsouaka RA, Bhatt DL, Heidenreich PA, Hernandez AF, et al. Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction: 5-Year Outcomes. J Am Coll Cardiol. 2017;70(20):2476-86. 7. Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KK, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med. 2002;347(18):1397-402. 8. Hernandez AF, Whellan DJ, Stroud S, Sun JL, O'Connor CM, Jollis JG. Outcomes in heart failure patients after major noncardiac surgery. J Am Coll Cardiol. 2004;44(7):1446-53. 9. van Diepen S, Bakal JA, McAlister FA, Ezekowitz JA. Mortality and Readmission of Patients With Heart Failure, Atrial Fibrillation, or Coronary Artery Disease Undergoing Noncardiac Surgery. Circulation. 2011;124

Individual participant data

Plan to share: No — Not actual in this study concept

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Mar 2027, 7 months later.

Of 793 non-industry observational studies under Heart Failure, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 99. This study's planned 7 months is below that.

Counting every sponsor, half of 975 studies reached it within 41 months; a quarter within 23 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2026
First posted
Jun 9, 2026
StartEst.
Aug 2026
Primary completionEst.
Mar 2027
CompletionEst.
Dec 2030
Last update
Jun 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07634822
Lead sponsor
Umeå University
Collaborators
Region Norrbotten
Responsible party
Sponsor
First posted
Jun 9, 2026
Start date
Aug 2026 (estimated)
Primary completion
Mar 2027 (estimated)
Completion
Dec 2030 (estimated)
Last update
Jun 9, 2026

Study contacts

Tomi Myrberg, Associate professor
Contact
tomi.myrberg@umu.se
+46920282236

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Heart Failure →

Other studies from this sponsor

Umeå University →

Start the discussion